OCC
Diabetes Magna Plus™

A New Surgical Approach For Type 2 Diabetes

Diabetes Magna Plus combines bariatric and metabolic surgical principles designed to improve metabolic health and blood sugar control in appropriately selected patients.

See If You May Be A Candidate Request Consultation

Results vary among individuals. Medical evaluation is required.

Why Type 2 Diabetes is different

Type 2 Diabetes is not simply a problem of high blood sugar — it is a complex metabolic condition. Understanding this helps explain why combined treatment strategies, including metabolic surgery in appropriate candidates, are studied as part of long-term care.

Metabolic disease

Type 2 Diabetes is a chronic metabolic disease that affects how the body regulates glucose, insulin, and many other hormonal pathways.

More than weight

Blood sugar control involves more than weight alone — insulin sensitivity, beta-cell function, and gut hormones all play a role.

Multiple strategies

Patients often require a combination of lifestyle change, medications, and ongoing monitoring to reach individualized A1C goals.

Beyond medications

Many patients seek alternatives beyond continued medication escalation, especially when glucose control becomes harder to maintain.

What is Diabetes Magna Plus?

Diabetes Magna Plus combines several surgical and metabolic principles into a single program designed to support metabolic health and glucose regulation in appropriately selected patients.

Sleeve gastrectomy

A restrictive component that reduces stomach volume using a minimally invasive technique.

Metabolic surgical principles

Surgical strategies designed to influence metabolic, hormonal, and nutrient-signaling pathways relevant to glucose regulation.

MagDI technology

A magnetic duodeno-ileal diversion using paired magnets to create a controlled side-to-side intestinal connection.

Hormonal changes

The combined procedure is designed to influence gut hormones implicated in appetite, satiety, and insulin secretion.

Metabolic pathways

Nutrient routing may modify signals between the gut, pancreas, liver, and brain that regulate glucose and energy balance.

How it works

Diabetes Magna Plus is designed to act on multiple pathways relevant to metabolic disease. Mechanisms continue to be characterized in published and ongoing research.

  1. 1

    Hormonal signaling

    Modifying the path of nutrients through the intestine may influence release of incretin and other gut hormones involved in insulin response.

  2. 2

    Insulin sensitivity

    Weight loss combined with metabolic effects may contribute to improved insulin sensitivity in muscle, liver, and adipose tissue.

  3. 3

    Glucose regulation

    Some patients experience improvements in fasting glucose and A1C; outcomes vary and require ongoing monitoring.

  4. 4

    Appetite regulation

    Restrictive and hormonal effects may support appetite regulation, satiety, and reduced caloric intake.

  5. 5

    Metabolic improvement

    Improvements may extend beyond glucose alone to other components of metabolic health, including lipids and blood pressure.

Read about the mechanism of action

Current scientific evidence

The following educational summary highlights regulatory milestones, published research, and ongoing studies relevant to Diabetes Magna Plus and the MagDI platform. Published evidence continues to evolve.

FDA milestones

De Novo authorization (2024) and subsequent 510(k) clearances for the MagDI platform.

Learn more

Published studies

Peer-reviewed first-in-human and multicenter publications in bariatric and metabolic journals.

Learn more

Ongoing research

Active investigations evaluating safety, weight outcomes, and metabolic effects across multiple sites.

Learn more

ClinicalTrials.gov

Registered studies in adults with obesity and Type 2 Diabetes; see registrations for current status.

Learn more
Explore the Science

Who may be a candidate?

Candidacy for Diabetes Magna Plus is individualized. The criteria below are educational examples of factors a physician typically considers. Final determination requires in-person medical evaluation and review of medical history, laboratory data, and current treatment.

Detailed candidate selection
  • Diagnosis of Type 2 Diabetes
  • BMI above 30 (individualized by clinical judgment)
  • Insulin dependence or escalating medication regimen
  • Use of multiple diabetes or metabolic medications
  • Features of metabolic syndrome
  • Prior weight-loss interventions with insufficient long-term effect
  • Important: Final candidacy is determined by a qualified physician after individual evaluation. Results vary among individuals.

Risks and limitations

All surgical procedures carry risk. The list below summarizes potential complications and limitations associated with metabolic surgery. A complete discussion of risks is part of the informed-consent process with the surgical team. Long-term studies continue to be published.

  • Bleeding
  • Infection
  • Obstruction
  • Leak
  • Nutritional deficiencies
  • Need for additional treatment or reoperation
  • Failure to achieve expected outcomes
  • Anesthesia-related events
Safety & Risks page Contraindications

Frequently Asked Questions

Educational answers to common questions about Diabetes Magna Plus, MagDI, and metabolic surgery. Always speak with a qualified clinician about your individual situation.

Metabolic surgery refers to gastrointestinal procedures that are designed to influence the hormonal, neural, and nutrient-signaling pathways involved in glucose regulation, insulin sensitivity, appetite, and body weight. It is distinct from purely cosmetic or restrictive weight-loss procedures and is studied as a treatment strategy for obesity and Type 2 Diabetes in appropriately selected patients.
Editorial Oversight

Medical Review & Clinical Oversight

The educational content on this website is reviewed for medical accuracy, clarity, and patient safety by experienced bariatric and metabolic surgery professionals. The purpose of this review is to help ensure that information about obesity treatment, bariatric surgery, metabolic health, revisional surgery, endoscopic procedures, GLP-1 medications, and long-term follow-up is presented responsibly and without exaggerated claims.

Medical Reviewers

Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS
Bariatric & Metabolic Surgeon — Founder and Director, Obesity Control Center

Dr. Ariel Ortiz Lagardere is a bariatric and metabolic surgeon with extensive experience in minimally invasive weight-loss surgery, metabolic disease treatment, international patient care, and surgical education. Public professional profiles describe him as board-certified in Mexico, a Fellow of the American College of Surgeons, a Fellow of the American Society for Metabolic and Bariatric Surgery, and an SRC-recognized Master Surgeon in Metabolic and Bariatric Surgery.

Dr. Arturo Martinez Gamboa, MD
Bariatric & Metabolic Surgeon — Obesity Control Center

Dr. Arturo Martinez Gamboa has been affiliated with Obesity Control Center since 2001. His publicly available professional biography describes advanced laparoscopic and bariatric training at Hospital Ramón y Cajal in Madrid, Spain. Surgical Review Corporation sources identify him as an SRC-accredited Master Surgeon in Metabolic & Bariatric Surgery and Bariatric Revisional Surgery.

Dr. Helmuth Billy, MD
Bariatric & Revisional Surgery Specialist — Ventura, California

Dr. Helmuth Billy is a bariatric surgeon specializing in laparoscopic bariatric surgery, revisional bariatric surgery, and multidisciplinary weight-loss care. Public ASMBS meeting biographies describe him as being in private practice since 1997, actively practicing bariatric surgery since 2000, serving as medical director at two MBSAQIP hospitals, and having a clinical interest in weight regain and revisional surgery.

Editorial Review Process

All medical content is periodically reviewed for accuracy, relevance, readability, and consistency with current medical knowledge and accepted bariatric and metabolic surgery principles. Content is intended to support informed decision-making and does not replace consultation with a qualified healthcare professional.

Educational Disclaimer

This website provides general educational information only. It does not provide medical advice, diagnosis, treatment recommendations, or guarantees of outcome. Candidacy for any medical, surgical, endoscopic, or medication-based treatment must be determined by a qualified healthcare professional after an individual evaluation.

Last reviewed: June 2026

References

Selected authoritative sources informing our educational content. External links open in a new tab; we do not control or endorse third-party content.

Could metabolic surgery be part of your treatment plan?

Speak with our team to learn about metabolic surgery, candidacy, and available treatment pathways. Educational discussion only — final treatment decisions require an in-person medical evaluation.

By submitting, you agree to be contacted about educational information and consultation options. Results vary among individuals. Medical evaluation is required.

Book Consultation